(e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide has been researched along with Parkinson Disease in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Ding, F; Li, M; Tian, Y; Xu, Q; Zhang, M; Zhu, M | 1 |
1 other study(ies) available for (e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide and Parkinson Disease
Article | Year |
---|---|
Sensation of TRPV1 via 5-hydroxytryptamine signaling modulates pain hypersensitivity in a 6-hydroxydopamine induced mice model of Parkinson's disease.
Topics: Acrylamides; Animals; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Hyperalgesia; Male; Mice, Inbred C57BL; Oxidopamine; Pain Threshold; Parkinson Disease; Piperidines; Receptors, Serotonin, 5-HT3; Serotonin; Signal Transduction; Trigeminal Caudal Nucleus; TRPV Cation Channels | 2020 |